| pubmed-article:2221583 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0039005 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0242488 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0040018 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0772394 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0442123 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0427579 | lld:lifeskim |
| pubmed-article:2221583 | lifeskim:mentions | umls-concept:C0441509 | lld:lifeskim |
| pubmed-article:2221583 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2221583 | pubmed:dateCreated | 1990-11-15 | lld:pubmed |
| pubmed-article:2221583 | pubmed:abstractText | We hypothesized that thrombin activation may play a prominent role in endotoxin-induced secondary organ failure, such as acute lung injury. To test this hypothesis, we administered a thrombin-specific inhibitor, recombinant hirudin, in endotoxemic pigs. The pigs were anesthetized, mechanically ventilated, and prepared with Swan-Ganz and extravascular lung water (EVLW) catheters. A total of 18 randomly selected animals received a pretreatment of 1,000 U/kg of hirudin, followed by a continuous infusion over 6 h of 500 U/kg/h given simultaneously with the infusion of 10 micrograms/kg/h of Salmonella abortus equi endotoxin. Another 18 animals received a continuous infusion over 6 h of endotoxin but did not receive hirudin. All animals were fluid resuscitated with 17 ml/kg/h of saline for the duration of the experiment. Data are expressed as the mean (95% confidence interval). Hirudin reduced the endotoxin-induced consumption of plasma fibrinogen from -110 (-138 to -82) mg/100 ml to -39 (-67 to -12) mg/100 ml (p = 0.0001) and endotoxin-induced increases in the soluble fibrin in plasma from 434 (369 to 499) ng/ml to 236 (171 to 300) ng/ml (p = 0.0002). These data suggest an effective inhibition of the endotoxin-generated thrombin by hirudin. Furthermore, hirudin significantly reduced endotoxin-induced increases in pulmonary vascular resistance from 32 (27 to 37) kdyn x s x cm-5 x kg to 20 (15 to 25) kdyn x s x cm-5 x kg (p = 0.0015) and increases in EVLW from 15.4 (13.2 to 17.6) ml/kg to 12.2 (10.0 to 14.4) ml/kg (p = 0.0299).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2221583 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2221583 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2221583 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2221583 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2221583 | pubmed:issn | 0003-0805 | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:GRECOG FGF | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:GeigerRR | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:HoffmannHH | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:WeirBB | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:JochumMM | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:SiebeckMM | lld:pubmed |
| pubmed-article:2221583 | pubmed:author | pubmed-author:SpannaglMM | lld:pubmed |
| pubmed-article:2221583 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2221583 | pubmed:volume | 142 | lld:pubmed |
| pubmed-article:2221583 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2221583 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2221583 | pubmed:pagination | 782-8 | lld:pubmed |
| pubmed-article:2221583 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:meshHeading | pubmed-meshheading:2221583-... | lld:pubmed |
| pubmed-article:2221583 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2221583 | pubmed:articleTitle | Effect of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation and acute lung injury in pigs. | lld:pubmed |
| pubmed-article:2221583 | pubmed:affiliation | Department of Surgery, Ludwig Maximilians University, Munich, FRG. | lld:pubmed |
| pubmed-article:2221583 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2221583 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2221583 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2221583 | lld:pubmed |
